http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1825254-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_555896a2f43ea629dbc0f99b94cfd297 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-067 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-065 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-06 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2005-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0949243faa81d001c2e10f5d418447d8 |
| publicationDate | 2007-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1825254-A2 |
| titleOfInvention | Method for optimizing thiopurine efficacy and toxicity using mass spectrometry |
| abstract | The present invention relates to methods for optimizing therapeutic efficacy or reducing toxicity in a subject receiving any drug that can be metabolized to an active 6-mercapto-purine metabolite that has therapeutic efficacy such as 6-thioguanine nucleotide (6-TGN).Metabolic pathwaysare demonstratedon Figure 1. The methods provide determining 6-TGN and 6methylmercaptopurine nucleotide (6-MMPN) concentration levelsusing mass spectrometric methods, including LC-MS spectroscopy. |
| priorityDate | 2004-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 274.